.png)
- Top-line results from VEGA-3, a second phase 3 trial examining Viatris' (NASDAQ:VTRS) MR-141 (phentolamine ophthalmic solution) for presbyopia, indicate the candidate met its primary and all secondary endpoints.
- Data showed that significantly more patients in the treatment arm achieved the
English (US) ·